We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 2,343

USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients


Health Plans and Pharmacy Benefit Managers - Past and Future
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 13 2018

Historically, health plans and pharmacy benefit managers (“PBMs”) have been uncomfortable neighbors. Plans provide drug coverage, but contract out the


As potential trade war looms, nearly 1,300 U.S. imports from China may be subject to additional 25 percent tariffs under Section 301 and U.S. exports to China potentially subject to additional duties
  • Hogan Lovells
  • USA
  • April 6 2018

U.S. imports from China potentially subject to additional duties include certain chemicals, pharmaceutical products, medical devices, rubber, iron


Summary of Medicines Co. v. Hospira, Inc.
  • Sughrue Mion PLLC
  • USA
  • April 2 2018

In Medicines Co. v. Hospira, Inc. ("Medicines II"), the Federal Circuit held that a distribution agreement entered by Medicines Company ("MedCo") with


Enforcement and Litigation Strategies: Skadden’s Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar
  • Skadden Arps Slate Meagher & Flom LLP
  • USA
  • March 29 2018

On March 15, 2018, Skadden hosted its Eighth Annual Pharmaceutical, Biotechnology and Medical Device Seminar in Palo Alto, California, which focused


Pennsylvania Judge Throws Out Pharmaceutical Trade Secrets Lawsuit
  • Crowell & Moring LLP
  • USA
  • March 26 2018

A Pennsylvania federal judge grants Ex-PharMerica Executive’s motion for summary judgment. PharMerica, a company that provides long-term care pharmacy


Which Patent Trial and Appeal Board Trial Decisions Cannot be Appealed?
  • Banner & Witcoff Ltd
  • USA
  • March 26 2018

The U.S. Court of Appeals for the Federal Circuit heard oral arguments on March 6, 2018, in the appeal of Altaire Pharmaceuticals, Inc. v. Paragon


CMS Appoints Ombudsman to Handle PharmaceuticalTechnology Industry Concerns
  • Reed Smith LLP
  • USA
  • March 20 2018

James Bailey is the new CMS Medicare Pharmaceutical and Technology Ombudsman, a role Congress established in the 21st Century Cures Act to help


Top Developments in Hatch-Waxman Litigation for March 2018
  • Morrison & Foerster LLP
  • USA
  • March 13 2018

This month, we highlight several significant decisions including The Medicines Company v. Hospira, Inc. and Index Pharmaceuticals, LLC v. Gilead


Procedures and strategies for pharmaceutical brands: United States
  • Baker McKenzie
  • USA
  • March 13 2018

Clearing and registering pharmaceutical trademarks in the United States are often more complex and challenging than in other countries. This is due in